Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, has announced that its investigational tetravalent dengue vaccine is entering into a pediatric clinical study in Thailand to assess the efficacy of the vaccine in protecting children against dengue, the most widespread tropical disease after malaria.
Subscribe to our email newsletter
Sanofi Pasteur is collaborating with Mahidol University of Thailand, the Ministry of Public Health, and the Pediatric Dengue Vaccine Initiative to conduct this efficacy study in the province of Ratchaburi. The tetravalent dengue vaccine candidate is the first to reach this stage of clinical development, said Sanofi Pasteur.
The Sanofi Pasteur clinical study program follows guidelines from the Initiative for Vaccine Research (IVR) led by the World Health Organization (WHO), which fosters the global efforts towards dengue vaccine development.
Pratap Singhasivanon, dean of the faculty of Tropical Medicine, Mahidol University, said: “Large scale pediatric studies are instrumental for the development of a safe and efficacious dengue vaccine to protect against a disease that primarily affects children. We are happy to contribute to an important milestone with the actual start of an efficacy study in Ratchaburi.”